nodes	percent_of_prediction	percent_of_DWPC	metapath
Sibutramine—Hormone level abnormal—Thalidomide—leprosy	0.0532	0.0574	CcSEcCtD
Sibutramine—CYP3A4—Rifampicin—leprosy	0.0403	0.548	CbGbCtD
Sibutramine—CYP3A4—Dapsone—leprosy	0.0332	0.452	CbGbCtD
Sibutramine—Hangover—Thalidomide—leprosy	0.0213	0.023	CcSEcCtD
Sibutramine—Lacrimal structural disorder—Thalidomide—leprosy	0.0171	0.0184	CcSEcCtD
Sibutramine—Circumoral paresthesia—Thalidomide—leprosy	0.0154	0.0166	CcSEcCtD
Sibutramine—Albuminuria—Dapsone—leprosy	0.0131	0.0142	CcSEcCtD
Sibutramine—Lacrimal disorder—Thalidomide—leprosy	0.0112	0.0121	CcSEcCtD
Sibutramine—Hernia—Thalidomide—leprosy	0.0107	0.0115	CcSEcCtD
Sibutramine—Paraesthesia oral—Thalidomide—leprosy	0.0107	0.0115	CcSEcCtD
Sibutramine—Cerebral ischaemia—Thalidomide—leprosy	0.0104	0.0112	CcSEcCtD
Sibutramine—Peripheral vascular disorder—Thalidomide—leprosy	0.0102	0.011	CcSEcCtD
Sibutramine—Transient ischaemic attack—Thalidomide—leprosy	0.00993	0.0107	CcSEcCtD
Sibutramine—Hostility—Thalidomide—leprosy	0.00906	0.00977	CcSEcCtD
Sibutramine—Gastric ulcer—Thalidomide—leprosy	0.00863	0.00931	CcSEcCtD
Sibutramine—Enlargement abdomen—Thalidomide—leprosy	0.00833	0.00899	CcSEcCtD
Sibutramine—Psoriasis—Thalidomide—leprosy	0.00798	0.00861	CcSEcCtD
Sibutramine—Myasthenia—Thalidomide—leprosy	0.00798	0.00861	CcSEcCtD
Sibutramine—Hypothyroidism—Thalidomide—leprosy	0.00781	0.00843	CcSEcCtD
Sibutramine—Nail disorder—Thalidomide—leprosy	0.00773	0.00834	CcSEcCtD
Sibutramine—Tooth disorder—Thalidomide—leprosy	0.00773	0.00834	CcSEcCtD
Sibutramine—Intestinal obstruction—Thalidomide—leprosy	0.00736	0.00794	CcSEcCtD
Sibutramine—Menstrual disorder—Thalidomide—leprosy	0.00736	0.00794	CcSEcCtD
Sibutramine—Neuralgia—Thalidomide—leprosy	0.00722	0.00779	CcSEcCtD
Sibutramine—Lung disorder—Thalidomide—leprosy	0.00708	0.00765	CcSEcCtD
Sibutramine—Metrorrhagia—Thalidomide—leprosy	0.00702	0.00758	CcSEcCtD
Sibutramine—Hyperlipidaemia—Thalidomide—leprosy	0.00696	0.00751	CcSEcCtD
Sibutramine—Psychotic disorder—Dapsone—leprosy	0.00694	0.00749	CcSEcCtD
Sibutramine—Neuritis—Thalidomide—leprosy	0.00672	0.00725	CcSEcCtD
Sibutramine—Albuminuria—Thalidomide—leprosy	0.00672	0.00725	CcSEcCtD
Sibutramine—Amblyopia—Thalidomide—leprosy	0.00649	0.00701	CcSEcCtD
Sibutramine—Skin ulcer—Thalidomide—leprosy	0.00644	0.00695	CcSEcCtD
Sibutramine—Rash pustular—Thalidomide—leprosy	0.00629	0.00678	CcSEcCtD
Sibutramine—Muscular weakness—Dapsone—leprosy	0.00627	0.00677	CcSEcCtD
Sibutramine—Influenza—Dapsone—leprosy	0.00614	0.00663	CcSEcCtD
Sibutramine—Petechiae—Thalidomide—leprosy	0.00609	0.00658	CcSEcCtD
Sibutramine—Acne—Thalidomide—leprosy	0.00596	0.00643	CcSEcCtD
Sibutramine—Apnoea—Thalidomide—leprosy	0.00591	0.00638	CcSEcCtD
Sibutramine—Vasodilation—Thalidomide—leprosy	0.00571	0.00616	CcSEcCtD
Sibutramine—Vasodilation procedure—Thalidomide—leprosy	0.00571	0.00616	CcSEcCtD
Sibutramine—Amenorrhoea—Thalidomide—leprosy	0.00571	0.00616	CcSEcCtD
Sibutramine—Accidental injury—Thalidomide—leprosy	0.00567	0.00612	CcSEcCtD
Sibutramine—Photosensitivity reaction—Dapsone—leprosy	0.00561	0.00605	CcSEcCtD
Sibutramine—Bone disorder—Thalidomide—leprosy	0.00555	0.00599	CcSEcCtD
Sibutramine—Cellulitis—Thalidomide—leprosy	0.00551	0.00595	CcSEcCtD
Sibutramine—Hyperbilirubinaemia—Thalidomide—leprosy	0.00551	0.00595	CcSEcCtD
Sibutramine—Arthropathy—Thalidomide—leprosy	0.00551	0.00595	CcSEcCtD
Sibutramine—Thinking abnormal—Thalidomide—leprosy	0.00548	0.00591	CcSEcCtD
Sibutramine—Herpes simplex—Thalidomide—leprosy	0.00544	0.00587	CcSEcCtD
Sibutramine—Hyperuricaemia—Thalidomide—leprosy	0.0054	0.00583	CcSEcCtD
Sibutramine—Neuropathy peripheral—Dapsone—leprosy	0.00537	0.0058	CcSEcCtD
Sibutramine—Leukocytosis—Thalidomide—leprosy	0.00533	0.00576	CcSEcCtD
Sibutramine—Hypercholesterolaemia—Thalidomide—leprosy	0.0053	0.00572	CcSEcCtD
Sibutramine—Creatinine increased—Thalidomide—leprosy	0.00527	0.00568	CcSEcCtD
Sibutramine—Bone pain—Thalidomide—leprosy	0.00523	0.00565	CcSEcCtD
Sibutramine—Sinusitis—Dapsone—leprosy	0.00514	0.00555	CcSEcCtD
Sibutramine—Gait disturbance—Thalidomide—leprosy	0.00514	0.00554	CcSEcCtD
Sibutramine—Blood uric acid increased—Thalidomide—leprosy	0.00511	0.00551	CcSEcCtD
Sibutramine—Neck pain—Thalidomide—leprosy	0.00507	0.00548	CcSEcCtD
Sibutramine—Phosphatase alkaline increased—Thalidomide—leprosy	0.00501	0.00541	CcSEcCtD
Sibutramine—Hyperkalaemia—Thalidomide—leprosy	0.00493	0.00532	CcSEcCtD
Sibutramine—Eructation—Thalidomide—leprosy	0.00493	0.00532	CcSEcCtD
Sibutramine—Pharyngitis—Dapsone—leprosy	0.00488	0.00527	CcSEcCtD
Sibutramine—Colitis—Thalidomide—leprosy	0.00481	0.0052	CcSEcCtD
Sibutramine—Blood urea increased—Thalidomide—leprosy	0.00473	0.00511	CcSEcCtD
Sibutramine—Dry eye—Thalidomide—leprosy	0.00463	0.005	CcSEcCtD
Sibutramine—Cramps of lower extremities—Thalidomide—leprosy	0.00461	0.00497	CcSEcCtD
Sibutramine—Tinnitus—Dapsone—leprosy	0.00459	0.00495	CcSEcCtD
Sibutramine—Oesophagitis—Thalidomide—leprosy	0.00458	0.00494	CcSEcCtD
Sibutramine—Hypertonia—Thalidomide—leprosy	0.00439	0.00474	CcSEcCtD
Sibutramine—Hyperkinesia—Thalidomide—leprosy	0.00437	0.00472	CcSEcCtD
Sibutramine—Mental disability—Thalidomide—leprosy	0.00435	0.0047	CcSEcCtD
Sibutramine—Sepsis—Thalidomide—leprosy	0.00435	0.0047	CcSEcCtD
Sibutramine—Euphoric mood—Thalidomide—leprosy	0.00431	0.00465	CcSEcCtD
Sibutramine—Lymphadenopathy—Thalidomide—leprosy	0.00427	0.0046	CcSEcCtD
Sibutramine—Diabetes mellitus—Thalidomide—leprosy	0.00418	0.00452	CcSEcCtD
Sibutramine—Blood alkaline phosphatase increased—Thalidomide—leprosy	0.00418	0.00452	CcSEcCtD
Sibutramine—Photosensitivity—Thalidomide—leprosy	0.00414	0.00447	CcSEcCtD
Sibutramine—Gastroenteritis—Thalidomide—leprosy	0.00411	0.00443	CcSEcCtD
Sibutramine—Vascular purpura—Thalidomide—leprosy	0.00407	0.00439	CcSEcCtD
Sibutramine—Eczema—Thalidomide—leprosy	0.00405	0.00437	CcSEcCtD
Sibutramine—Vision blurred—Dapsone—leprosy	0.00404	0.00435	CcSEcCtD
Sibutramine—Eye pain—Thalidomide—leprosy	0.00403	0.00435	CcSEcCtD
Sibutramine—Cardiac failure congestive—Thalidomide—leprosy	0.00401	0.00433	CcSEcCtD
Sibutramine—Injury—Thalidomide—leprosy	0.00396	0.00427	CcSEcCtD
Sibutramine—Libido decreased—Thalidomide—leprosy	0.00392	0.00424	CcSEcCtD
Sibutramine—Increased appetite—Thalidomide—leprosy	0.00387	0.00418	CcSEcCtD
Sibutramine—Amnesia—Thalidomide—leprosy	0.00387	0.00418	CcSEcCtD
Sibutramine—Vertigo—Dapsone—leprosy	0.00385	0.00415	CcSEcCtD
Sibutramine—Atrial fibrillation—Thalidomide—leprosy	0.00384	0.00414	CcSEcCtD
Sibutramine—Dermatitis bullous—Thalidomide—leprosy	0.00381	0.00411	CcSEcCtD
Sibutramine—Purpura—Thalidomide—leprosy	0.00378	0.00408	CcSEcCtD
Sibutramine—Arthritis—Thalidomide—leprosy	0.00374	0.00404	CcSEcCtD
Sibutramine—Cough—Dapsone—leprosy	0.00374	0.00403	CcSEcCtD
Sibutramine—Hypoglycaemia—Thalidomide—leprosy	0.00373	0.00402	CcSEcCtD
Sibutramine—Cerebrovascular accident—Thalidomide—leprosy	0.00371	0.00401	CcSEcCtD
Sibutramine—Pain in extremity—Thalidomide—leprosy	0.00364	0.00393	CcSEcCtD
Sibutramine—Osteoarthritis—Thalidomide—leprosy	0.00364	0.00393	CcSEcCtD
Sibutramine—Gastrointestinal haemorrhage—Thalidomide—leprosy	0.00364	0.00393	CcSEcCtD
Sibutramine—Disturbance in sexual arousal—Thalidomide—leprosy	0.00361	0.0039	CcSEcCtD
Sibutramine—Affect lability—Thalidomide—leprosy	0.00358	0.00387	CcSEcCtD
Sibutramine—Migraine—Thalidomide—leprosy	0.00358	0.00387	CcSEcCtD
Sibutramine—Psychotic disorder—Thalidomide—leprosy	0.00355	0.00384	CcSEcCtD
Sibutramine—Face oedema—Thalidomide—leprosy	0.00351	0.00379	CcSEcCtD
Sibutramine—Cardiac arrest—Thalidomide—leprosy	0.00346	0.00374	CcSEcCtD
Sibutramine—Mood swings—Thalidomide—leprosy	0.00345	0.00372	CcSEcCtD
Sibutramine—Ataxia—Thalidomide—leprosy	0.00342	0.00369	CcSEcCtD
Sibutramine—Tachycardia—Dapsone—leprosy	0.00341	0.00368	CcSEcCtD
Sibutramine—Blood creatinine increased—Thalidomide—leprosy	0.00341	0.00368	CcSEcCtD
Sibutramine—Dehydration—Thalidomide—leprosy	0.00338	0.00365	CcSEcCtD
Sibutramine—Liver function test abnormal—Thalidomide—leprosy	0.00336	0.00363	CcSEcCtD
Sibutramine—Dry skin—Thalidomide—leprosy	0.00334	0.0036	CcSEcCtD
Sibutramine—Orthostatic hypotension—Thalidomide—leprosy	0.00332	0.00359	CcSEcCtD
Sibutramine—Hypokalaemia—Thalidomide—leprosy	0.00331	0.00357	CcSEcCtD
Sibutramine—Aspartate aminotransferase increased—Thalidomide—leprosy	0.00328	0.00354	CcSEcCtD
Sibutramine—Alanine aminotransferase increased—Thalidomide—leprosy	0.00321	0.00346	CcSEcCtD
Sibutramine—Muscular weakness—Thalidomide—leprosy	0.00321	0.00346	CcSEcCtD
Sibutramine—Abdominal distension—Thalidomide—leprosy	0.00317	0.00342	CcSEcCtD
Sibutramine—Insomnia—Dapsone—leprosy	0.00316	0.00341	CcSEcCtD
Sibutramine—Influenza—Thalidomide—leprosy	0.00315	0.00339	CcSEcCtD
Sibutramine—Dysphagia—Thalidomide—leprosy	0.00315	0.00339	CcSEcCtD
Sibutramine—Eosinophilia—Thalidomide—leprosy	0.00311	0.00336	CcSEcCtD
Sibutramine—Angina pectoris—Thalidomide—leprosy	0.00306	0.00331	CcSEcCtD
Sibutramine—Bronchitis—Thalidomide—leprosy	0.00303	0.00326	CcSEcCtD
Sibutramine—Pollakiuria—Thalidomide—leprosy	0.00291	0.00314	CcSEcCtD
Sibutramine—Erectile dysfunction—Thalidomide—leprosy	0.0029	0.00313	CcSEcCtD
Sibutramine—Photosensitivity reaction—Thalidomide—leprosy	0.00287	0.0031	CcSEcCtD
Sibutramine—Weight increased—Thalidomide—leprosy	0.00286	0.00309	CcSEcCtD
Sibutramine—Gastrointestinal pain—Dapsone—leprosy	0.00286	0.00308	CcSEcCtD
Sibutramine—Hyperglycaemia—Thalidomide—leprosy	0.00284	0.00306	CcSEcCtD
Sibutramine—Pneumonia—Thalidomide—leprosy	0.00282	0.00304	CcSEcCtD
Sibutramine—Depression—Thalidomide—leprosy	0.0028	0.00302	CcSEcCtD
Sibutramine—Acute coronary syndrome—Thalidomide—leprosy	0.00276	0.00298	CcSEcCtD
Sibutramine—Abdominal pain—Dapsone—leprosy	0.00276	0.00298	CcSEcCtD
Sibutramine—Body temperature increased—Dapsone—leprosy	0.00276	0.00298	CcSEcCtD
Sibutramine—Renal failure—Thalidomide—leprosy	0.00276	0.00298	CcSEcCtD
Sibutramine—Neuropathy peripheral—Thalidomide—leprosy	0.00275	0.00297	CcSEcCtD
Sibutramine—Myocardial infarction—Thalidomide—leprosy	0.00275	0.00297	CcSEcCtD
Sibutramine—Stomatitis—Thalidomide—leprosy	0.00273	0.00295	CcSEcCtD
Sibutramine—Conjunctivitis—Thalidomide—leprosy	0.00273	0.00294	CcSEcCtD
Sibutramine—Sweating—Thalidomide—leprosy	0.00269	0.0029	CcSEcCtD
Sibutramine—Haematuria—Thalidomide—leprosy	0.00267	0.00289	CcSEcCtD
Sibutramine—Epistaxis—Thalidomide—leprosy	0.00265	0.00286	CcSEcCtD
Sibutramine—Sinusitis—Thalidomide—leprosy	0.00263	0.00284	CcSEcCtD
Sibutramine—Bradycardia—Thalidomide—leprosy	0.00256	0.00277	CcSEcCtD
Sibutramine—Rhinitis—Thalidomide—leprosy	0.00252	0.00272	CcSEcCtD
Sibutramine—Hypoaesthesia—Thalidomide—leprosy	0.00251	0.0027	CcSEcCtD
Sibutramine—Pharyngitis—Thalidomide—leprosy	0.0025	0.0027	CcSEcCtD
Sibutramine—Oedema peripheral—Thalidomide—leprosy	0.00248	0.00268	CcSEcCtD
Sibutramine—Visual impairment—Thalidomide—leprosy	0.00243	0.00262	CcSEcCtD
Sibutramine—Eye disorder—Thalidomide—leprosy	0.00235	0.00254	CcSEcCtD
Sibutramine—Tinnitus—Thalidomide—leprosy	0.00235	0.00253	CcSEcCtD
Sibutramine—Angiopathy—Thalidomide—leprosy	0.00228	0.00247	CcSEcCtD
Sibutramine—Immune system disorder—Thalidomide—leprosy	0.00227	0.00245	CcSEcCtD
Sibutramine—Chills—Thalidomide—leprosy	0.00226	0.00244	CcSEcCtD
Sibutramine—Arrhythmia—Thalidomide—leprosy	0.00225	0.00243	CcSEcCtD
Sibutramine—Alopecia—Thalidomide—leprosy	0.00222	0.0024	CcSEcCtD
Sibutramine—Vomiting—Dapsone—leprosy	0.00222	0.0024	CcSEcCtD
Sibutramine—Malnutrition—Thalidomide—leprosy	0.00219	0.00237	CcSEcCtD
Sibutramine—Headache—Dapsone—leprosy	0.00219	0.00236	CcSEcCtD
Sibutramine—Flatulence—Thalidomide—leprosy	0.00216	0.00233	CcSEcCtD
Sibutramine—Tension—Thalidomide—leprosy	0.00215	0.00232	CcSEcCtD
Sibutramine—Dysgeusia—Thalidomide—leprosy	0.00215	0.00232	CcSEcCtD
Sibutramine—Nervousness—Thalidomide—leprosy	0.00213	0.0023	CcSEcCtD
Sibutramine—Back pain—Thalidomide—leprosy	0.00212	0.00229	CcSEcCtD
Sibutramine—Muscle spasms—Thalidomide—leprosy	0.00211	0.00227	CcSEcCtD
Sibutramine—Nausea—Dapsone—leprosy	0.00208	0.00224	CcSEcCtD
Sibutramine—Vision blurred—Thalidomide—leprosy	0.00207	0.00223	CcSEcCtD
Sibutramine—Tremor—Thalidomide—leprosy	0.00205	0.00222	CcSEcCtD
Sibutramine—Ill-defined disorder—Thalidomide—leprosy	0.00203	0.00219	CcSEcCtD
Sibutramine—Anaemia—Thalidomide—leprosy	0.00203	0.00219	CcSEcCtD
Sibutramine—Agitation—Thalidomide—leprosy	0.00201	0.00217	CcSEcCtD
Sibutramine—Angioedema—Thalidomide—leprosy	0.002	0.00216	CcSEcCtD
Sibutramine—Malaise—Thalidomide—leprosy	0.00198	0.00213	CcSEcCtD
Sibutramine—Vertigo—Thalidomide—leprosy	0.00197	0.00213	CcSEcCtD
Sibutramine—Syncope—Thalidomide—leprosy	0.00197	0.00212	CcSEcCtD
Sibutramine—Leukopenia—Thalidomide—leprosy	0.00196	0.00212	CcSEcCtD
Sibutramine—Palpitations—Thalidomide—leprosy	0.00194	0.00209	CcSEcCtD
Sibutramine—Loss of consciousness—Thalidomide—leprosy	0.00193	0.00208	CcSEcCtD
Sibutramine—Cough—Thalidomide—leprosy	0.00191	0.00206	CcSEcCtD
Sibutramine—Convulsion—Thalidomide—leprosy	0.0019	0.00205	CcSEcCtD
Sibutramine—Hypertension—Thalidomide—leprosy	0.00189	0.00204	CcSEcCtD
Sibutramine—Arthralgia—Thalidomide—leprosy	0.00187	0.00201	CcSEcCtD
Sibutramine—Myalgia—Thalidomide—leprosy	0.00187	0.00201	CcSEcCtD
Sibutramine—Chest pain—Thalidomide—leprosy	0.00187	0.00201	CcSEcCtD
Sibutramine—Anxiety—Thalidomide—leprosy	0.00186	0.00201	CcSEcCtD
Sibutramine—Discomfort—Thalidomide—leprosy	0.00184	0.00199	CcSEcCtD
Sibutramine—Dry mouth—Thalidomide—leprosy	0.00182	0.00197	CcSEcCtD
Sibutramine—Confusional state—Thalidomide—leprosy	0.0018	0.00195	CcSEcCtD
Sibutramine—Oedema—Thalidomide—leprosy	0.00179	0.00193	CcSEcCtD
Sibutramine—Infection—Thalidomide—leprosy	0.00178	0.00192	CcSEcCtD
Sibutramine—Shock—Thalidomide—leprosy	0.00176	0.0019	CcSEcCtD
Sibutramine—Thrombocytopenia—Thalidomide—leprosy	0.00175	0.00189	CcSEcCtD
Sibutramine—Tachycardia—Thalidomide—leprosy	0.00175	0.00188	CcSEcCtD
Sibutramine—Skin disorder—Thalidomide—leprosy	0.00174	0.00188	CcSEcCtD
Sibutramine—Hyperhidrosis—Thalidomide—leprosy	0.00173	0.00187	CcSEcCtD
Sibutramine—Anorexia—Thalidomide—leprosy	0.00171	0.00184	CcSEcCtD
Sibutramine—Hypotension—Thalidomide—leprosy	0.00167	0.0018	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Thalidomide—leprosy	0.00163	0.00176	CcSEcCtD
Sibutramine—Insomnia—Thalidomide—leprosy	0.00162	0.00175	CcSEcCtD
Sibutramine—Paraesthesia—Thalidomide—leprosy	0.00161	0.00173	CcSEcCtD
Sibutramine—Dyspnoea—Thalidomide—leprosy	0.00159	0.00172	CcSEcCtD
Sibutramine—Somnolence—Thalidomide—leprosy	0.00159	0.00172	CcSEcCtD
Sibutramine—Dyspepsia—Thalidomide—leprosy	0.00157	0.0017	CcSEcCtD
Sibutramine—Decreased appetite—Thalidomide—leprosy	0.00155	0.00168	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Thalidomide—leprosy	0.00154	0.00167	CcSEcCtD
Sibutramine—Pain—Thalidomide—leprosy	0.00153	0.00165	CcSEcCtD
Sibutramine—Constipation—Thalidomide—leprosy	0.00153	0.00165	CcSEcCtD
Sibutramine—Feeling abnormal—Thalidomide—leprosy	0.00147	0.00159	CcSEcCtD
Sibutramine—Gastrointestinal pain—Thalidomide—leprosy	0.00146	0.00158	CcSEcCtD
Sibutramine—Urticaria—Thalidomide—leprosy	0.00142	0.00153	CcSEcCtD
Sibutramine—Body temperature increased—Thalidomide—leprosy	0.00141	0.00153	CcSEcCtD
Sibutramine—Abdominal pain—Thalidomide—leprosy	0.00141	0.00153	CcSEcCtD
Sibutramine—Hypersensitivity—Thalidomide—leprosy	0.00132	0.00142	CcSEcCtD
Sibutramine—Asthenia—Thalidomide—leprosy	0.00128	0.00139	CcSEcCtD
Sibutramine—Pruritus—Thalidomide—leprosy	0.00127	0.00137	CcSEcCtD
Sibutramine—Diarrhoea—Thalidomide—leprosy	0.00122	0.00132	CcSEcCtD
Sibutramine—Dizziness—Thalidomide—leprosy	0.00118	0.00128	CcSEcCtD
Sibutramine—Vomiting—Thalidomide—leprosy	0.00114	0.00123	CcSEcCtD
Sibutramine—Rash—Thalidomide—leprosy	0.00113	0.00122	CcSEcCtD
Sibutramine—Dermatitis—Thalidomide—leprosy	0.00113	0.00122	CcSEcCtD
Sibutramine—Headache—Thalidomide—leprosy	0.00112	0.00121	CcSEcCtD
Sibutramine—Nausea—Thalidomide—leprosy	0.00106	0.00115	CcSEcCtD
